Skip to main content

Drug Interactions between dolutegravir and Wilzin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

zinc acetate dolutegravir

Applies to: Wilzin (zinc acetate) and dolutegravir

ADJUST DOSING INTERVAL: Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs). The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.

MANAGEMENT: If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.

References

  1. (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare
  2. (2018) "Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir)." Gilead Sciences
  3. US National Library of Medicine (2019) Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions

Switch to consumer interaction data

Drug and food interactions

Moderate

zinc acetate food

Applies to: Wilzin (zinc acetate)

ADJUST DOSING INTERVAL: The presence of certain foods (e.g., bread, bran, hard boiled eggs, coffee, and milk) may significantly delay the absorption of zinc acetate. Fibres, phytates, and other substances in food prevent zinc from entering intestinal cells by binding with it. Protein does not appear to interfere with its absorption.

MANAGEMENT: Zinc acetate should preferably be taken on an empty stomach, at least one hour before or two to three hours after meals. It may be taken with small amounts of protein such as meat.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Minor

dolutegravir food

Applies to: dolutegravir

Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.

References

  1. (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer